S. H. Swerdlow, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, pp.2375-2390, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01800015

M. Hallek, . German-cll-study, and . Group, Prognostic factors in chronic lymphocytic leukemia, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol, vol.19, pp.51-53, 2008.

C. International and . Group, An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data, Lancet Oncol, vol.17, pp.779-790, 2016.

M. Hallek, Chronic lymphocytic leukemia: 2019 update on diagnosis, risk stratification and treatment, Am. J. Hematol, 2019.

D. Brander, P. Islam, and J. C. Barrientos, Tailored Treatment Strategies for Chronic Lymphocytic Leukemia in a Rapidly Changing Era, Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Annu. Meet, vol.39, pp.487-498, 2019.

N. Jain, Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options, Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Annu. Meet, vol.38, pp.580-591, 2018.

K. R. Rai and P. Jain, Chronic lymphocytic leukemia (CLL)-Then and now, Am. J. Hematol, vol.91, pp.330-340, 2016.

J. L. Binet, A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis, Cancer, vol.48, pp.198-206, 1981.

M. Crespo, ZAP-70 expression as a surrogate for immunoglobulin-variableregion mutations in chronic lymphocytic leukemia, N. Engl. J. Med, vol.348, pp.1764-1775, 2003.

D. Rossi, Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia, Blood, vol.121, pp.1403-1412, 2013.

P. Cramer and M. Hallek, Prognostic factors in chronic lymphocytic leukemia-what do we need to know?, Nat. Rev. Clin. Oncol, vol.8, pp.38-47, 2011.

M. Hallek, iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL, Blood, vol.131, pp.2745-2760, 2018.

J. C. Byrd, Targeting CD20 takes the backseat in CLL, Blood, vol.133, pp.1003-1004, 2019.

J. C. Byrd, Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia, N. Engl. J. Med, vol.369, pp.32-42, 2013.

J. C. Byrd, Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia, N. Engl. J. Med, vol.371, pp.213-223, 2014.

G. Ferrer and E. Montserrat, Critical molecular pathways in CLL therapy, Mol. Med. Camb. Mass, vol.24, p.9, 2018.

J. R. Brown, Relapsed CLL: sequencing, combinations, and novel agents, Hematol. Am. Soc. Hematol. Educ, pp.248-255, 2018.

R. R. Furman, Ibrutinib resistance in chronic lymphocytic leukemia, N. Engl. J. Med, vol.370, pp.2352-2354, 2014.

D. A. Bond and J. A. Woyach, Targeting BTK in CLL: Beyond Ibrutinib, Curr. Hematol. Malig. Rep, 2019.

J. A. Woyach, Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib, N. Engl. J. Med, vol.370, pp.2286-2294, 2014.

C. International and . Group, An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data, Lancet Oncol, vol.17, pp.779-790, 2016.

C. Schleiss, BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo, Sci. Rep, vol.9, p.701, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02290791

L. Lagneaux, A. Delforge, D. Bron, C. De-bruyn, and P. Stryckmans, Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells, Blood, vol.91, pp.2387-2396, 1998.

M. Ciccone, A. Ferrajoli, M. J. Keating, and G. A. Calin, SnapShot: chronic lymphocytic leukemia, Cancer Cell, vol.26, 2014.

E. Ten-hacken, R. Guièze, C. J. Wu, and . Snapshot, Chronic Lymphocytic Leukemia, vol.32, p.1, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01659737

G. Fabbri and R. Dalla-favera, The molecular pathogenesis of chronic lymphocytic leukaemia, Nat. Rev. Cancer, vol.16, pp.145-162, 2016.

U. Klein and R. Dalla-favera, New insights into the pathogenesis of chronic lymphocytic leukemia, Semin. Cancer Biol, vol.20, pp.377-383, 2010.

T. J. Kipps, Chronic lymphocytic leukaemia, Nat. Rev. Dis. Primer, vol.3, p.16096, 2017.

A. Rosenwald, Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia, J. Exp. Med, vol.194, pp.1639-1647, 2001.

K. D. Jayappa, Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL, Blood Adv, vol.1, pp.933-946, 2017.

N. A. Heerema, Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study, Cancer Genet. Cytogenet, vol.203, pp.134-140, 2010.

K. Crassini, W. S. Stevenson, S. P. Mulligan, and O. G. Best, Molecular pathogenesis of chronic lymphocytic leukaemia, Br. J. Haematol, vol.0

T. Decker, C. Bogner, M. Oelsner, C. Peschel, and I. Ringshausen, Antiapoptotic effect of interleukin-2 (IL-2) in B-CLL cells with low and high affinity IL-2 receptors, Ann. Hematol, vol.89, pp.1125-1132, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00545664

M. Plander, Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles, Leukemia, vol.23, pp.2118-2128, 2009.

K. Bojarczuk, BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199, Blood, vol.127, pp.3192-3201, 2016.

G. S. Choudhary, MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies, Cell Death Dis, vol.6, p.1593, 2015.

H. V. Vangapandu, The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells, Neoplasia N. Y. N, vol.19, pp.762-771, 2017.

H. V. Vangapandu, Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells, Oncotarget, vol.9, pp.24980-24991, 2018.

R. Jitschin, Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia, Blood, vol.123, pp.2663-2672, 2014.

A. Luengo, D. Y. Gui, and M. G. Vander-heiden, Targeting Metabolism for Cancer Therapy, Cell Chem. Biol, vol.24, pp.1161-1180, 2017.

M. G. Vander-heiden, L. C. Cantley, and C. B. Thompson, Understanding the Warburg effect: the metabolic requirements of cell proliferation, Science, vol.324, pp.1029-1033, 2009.

X. D. Xu, Warburg effect or reverse Warburg effect? A review of cancer metabolism, Oncol. Res. Treat, vol.38, pp.117-122, 2015.

S. Monti, Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response, Blood, vol.105, pp.1851-1861, 2005.

P. Caro, Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma, Cancer Cell, vol.22, pp.547-560, 2012.

C. T. Hensley, Metabolic Heterogeneity in Human Lung Tumors, Cell, vol.164, pp.681-694, 2016.

A. Viale, Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function, Nature, vol.514, pp.628-632, 2014.

T. Farge, Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism, Cancer Discov, vol.7, pp.716-735, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02465205

E. M. Kuntz, Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells, Nat. Med, vol.23, pp.1234-1240, 2017.

J. Chiche, GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors, Cell Metab, vol.29, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02359440

M. Rogne, Cytokinesis arrest and multiple centrosomes in B cell chronic lymphocytic leukaemia, J. Cell. Mol. Med, vol.22, pp.2846-2855, 2018.

M. A. Swartz, The physiology of the lymphatic system, Adv. Drug Deliv. Rev, vol.50, pp.3-20, 2001.

U. H. Von-andrian and T. R. Mempel, Homing and cellular traffic in lymph nodes, Nat. Rev. Immunol, vol.3, pp.867-878, 2003.

C. D. Allen, T. Okada, and J. G. Cyster, Germinal-center organization and cellular dynamics, Immunity, vol.27, pp.190-202, 2007.

E. Hamilton, Mimicking the tumour microenvironment: three different coculture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells, Br. J. Haematol, vol.158, pp.589-599, 2012.

D. Primo, A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia, Oncotarget, vol.9, pp.26019-26031, 2018.

N. Purroy, Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo, Oncotarget, vol.6, pp.7632-7643, 2014.

R. Buhmann, A. Nolte, D. Westhaus, B. Emmerich, and M. Hallek, CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells, Blood, vol.93, pp.1992-2002, 1999.

A. A. Filip, Circulating microenvironment of CLL: are nurse-like cells related to tumor-associated macrophages?, Blood Cells. Mol. Dis, vol.50, pp.263-270, 2013.

L. Lagneaux, A. Delforge, D. Bron, C. De-bruyn, and P. Stryckmans, Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells, Blood, vol.91, pp.2387-2396, 1998.

F. R. Dick and R. D. Maca, The lymph node in chronic lymphocytic leukemia, Cancer, vol.41, pp.283-292, 1978.

Y. Herishanu, The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia, Blood, vol.117, pp.563-574, 2011.

. Annexes,

, Annexe 1 : Score de Matutes

, Annexe 2 : Classification de Binet

, Annexe 3 : Pronostic de la LLC